RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Miskowiak, K W, Seeberg, I, Jensen, M B, Balanzá-Martínez, V, del Mar Bonnin, C, Bowie, C R, Carvalho, A F, Dols, A, Douglas, K, Gallagher, P, Hasler, G, Lafer, B, Lewandowski, K E, López-Jaramillo, C, Martinez-Aran, A, McIntyre, R S, Porter, R J, Purdon, S E, Schaffer, A, Stokes, P, Sumiyoshi, T, Torres, I J, van Rheenen, T E, Yatham, L N, Young, A H, Kessing, L V, Burdick, K E & Vieta, E 2022, ' Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021 : A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force ', Bipolar Disorders, vol. 24, no. 4, pp. 354-374 . https://doi.org/10.1111/bdi.13193 Miskowiak, K W, Seeberg, I, Jensen, M B, Balanzá-Martínez, V, del Mar Bonnin, C, Bowie, C R, Carvalho, A F, Dols, A, Douglas, K, Gallagher, P, Hasler, G, Lafer, B, Lewandowski, K E, López-Jaramillo, C, Martinez-Aran, A, McIntyre, R S, Porter, R J, Purdon, S E, Schaffer, A, Stokes, P, Sumiyoshi, T, Torres, I J, Van Rheenen, T E, Yatham, L N, Young, A H, Kessing, L V, Burdick, K E & Vieta, E 2022, ' Randomised controlled cognition trials in remitted patients with mood disorders published between 2015 and 2021 : A systematic review by the International Society for Bipolar Disorders Targeting Cognition Task Force ', Bipolar Disorders, vol. 24, no. 4, pp. 354-374 . https://doi.org/10.1111/bdi.13193
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Miskowiak, K W, Yalin, N, Seeberg, I, Burdick, K E, Balanzá-martínez, V, Bonnin, C D M, Bowie, C R, Carvalho, A F, Dols, A, Douglas, K, Gallagher, P, Hasler, G, Kessing, L V, Lafer, B, Lewandowski, K E, López-jaramillo, C, Martinez-aran, A, Mcintyre, R S, Porter, R J, Purdon, S E, Schaffer, A, Sumiyoshi, T, Torres, I J, Van Rheenen, T E, Yatham, L N, Young, A H, Vieta, E & Stokes, P R A 2022, ' Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force ', Bipolar Disorders, vol. 24, no. 6, pp. 615-636 . https://doi.org/10.1111/bdi.13247 Miskowiak, K W, Yalin, N, Seeberg, I, Burdick, K E, Balanzá-Martínez, V, Bonnin, C D M, Bowie, C R, Carvalho, A F, Dols, A, Douglas, K, Gallagher, P, Hasler, G, Kessing, L V, Lafer, B, Lewandowski, K E, López-Jaramillo, C, Martinez-Aran, A, McIntyre, R S, Porter, R J, Purdon, S E, Schaffer, A, Sumiyoshi, T, Torres, I J, van Rheenen, T E, Yatham, L N, Young, A H, Vieta, E & Stokes, P R A 2022, ' Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force ', Bipolar Disorders, vol. 24, no. 6, pp. 615-636 . https://doi.org/10.1111/bdi.13247